HUP0105132A3 - Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions - Google Patents

Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions

Info

Publication number
HUP0105132A3
HUP0105132A3 HU0105132A HUP0105132A HUP0105132A3 HU P0105132 A3 HUP0105132 A3 HU P0105132A3 HU 0105132 A HU0105132 A HU 0105132A HU P0105132 A HUP0105132 A HU P0105132A HU P0105132 A3 HUP0105132 A3 HU P0105132A3
Authority
HU
Hungary
Prior art keywords
preparing
pyrazinones
pyrido
pharmaceutical compositions
same
Prior art date
Application number
HU0105132A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Dresden Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Application filed by Dresden Arzneimittel filed Critical Dresden Arzneimittel
Publication of HUP0105132A2 publication Critical patent/HUP0105132A2/hu
Publication of HUP0105132A3 publication Critical patent/HUP0105132A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0105132A 1999-01-20 2000-01-14 Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions HUP0105132A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen

Publications (2)

Publication Number Publication Date
HUP0105132A2 HUP0105132A2 (hu) 2002-05-29
HUP0105132A3 true HUP0105132A3 (en) 2002-12-28

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105132A HUP0105132A3 (en) 1999-01-20 2000-01-14 Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions

Country Status (23)

Country Link
EP (1) EP1144410A2 (de)
JP (1) JP2002535330A (de)
KR (1) KR20010101603A (de)
CN (1) CN1344268A (de)
AR (1) AR022318A1 (de)
AU (1) AU2291200A (de)
BG (1) BG105714A (de)
BR (1) BR0007613A (de)
CA (1) CA2296224A1 (de)
CO (1) CO5190700A1 (de)
CZ (1) CZ20012627A3 (de)
EA (1) EA200100792A1 (de)
EE (1) EE200100377A (de)
HU (1) HUP0105132A3 (de)
ID (1) ID29790A (de)
IL (1) IL144156A0 (de)
IS (1) IS5987A (de)
LT (1) LT2001078A (de)
LV (1) LV12793B (de)
NO (1) NO20013334L (de)
SK (1) SK10322001A3 (de)
TR (1) TR200102121T2 (de)
WO (1) WO2000043392A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
JP2005513060A (ja) * 2001-12-17 2005-05-12 アルタナ　ファルマ　アクチエンゲゼルシャフト 選択的ｐｄｅ５阻害剤の新規使用
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
US8299080B2 (en) 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
KR20100110804A (ko) 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
WO2009070583A1 (en) * 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
EP3121178B1 (de) * 2011-10-10 2018-09-19 H. Lundbeck A/S 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one als pde9 inhibitor
WO2013110768A1 (en) 2012-01-26 2013-08-01 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
CN107810187B (zh) 2015-07-07 2020-09-15 H.隆德贝克有限公司 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
KR20010101603A (ko) 2001-11-14
CZ20012627A3 (cs) 2002-01-16
CA2296224A1 (en) 2000-07-20
TR200102121T2 (tr) 2002-01-21
WO2000043392A3 (de) 2000-09-28
SK10322001A3 (sk) 2002-07-02
ID29790A (id) 2001-10-11
HUP0105132A2 (hu) 2002-05-29
AU2291200A (en) 2000-08-07
IS5987A (is) 2001-06-29
IL144156A0 (en) 2002-05-23
CO5190700A1 (es) 2002-08-29
JP2002535330A (ja) 2002-10-22
LV12793A (lv) 2002-02-20
BG105714A (en) 2002-02-28
LV12793B (lv) 2002-05-20
EA200100792A1 (ru) 2002-10-31
CN1344268A (zh) 2002-04-10
AR022318A1 (es) 2002-09-04
EP1144410A2 (de) 2001-10-17
NO20013334D0 (no) 2001-07-05
LT2001078A (en) 2002-08-26
BR0007613A (pt) 2001-10-30
NO20013334L (no) 2001-07-05
WO2000043392A2 (de) 2000-07-27
EE200100377A (et) 2002-10-15

Similar Documents

Publication Publication Date Title
HUP0202494A2 (en) Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0200450A3 (en) Cephen derivatives containing an imidazo[4,5-b]pyridiniummethyl moiety, process for their preparation and pharmaceutical compositions of the same
HUP0105081A3 (en) Triazolo[4,5-d]pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0203450A3 (en) Pyrazolo '4,3-d! pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them and their use
HUP0100202A3 (en) Novel triazolo[4,5-d]pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0203142A3 (en) Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0203503A3 (en) Pyrrolo[2,3-d]pirimidine compounds, pharmaceutical compositions containing them and their use
IL128869A (en) ARYSULFONYL-SUBSTITUTED-PYRAZOLO [1,5-a]-PYRIMIDINE AND PYRAZOLO [1,5-a] [1, 3, 5]-TRIAZINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0204246A3 (en) Novel thiazolo[4,5-d]pyrimidine compounds, process for their preparation, pharmaceutical compositions containing them and their use
HUP0004708A3 (en) 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0200207A3 (en) Substituted 2-aryl-3-(hetroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compositions and methods for their preparation
HUP0202103A2 (en) 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives, their use, pharmaceutical compositions containing them, process for the preparation of the compounds and intermediates
HUP0004333A3 (en) Novel triazolo [4,5-d] pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing thereof
HUP0001507A3 (en) Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0203545A3 (en) Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives, pharmaceutical compositions containing them, process for their preparation and their use
HUP0401292A3 (en) Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
HUP0303350A3 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions
HUP0203052A3 (en) Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0202100A2 (en) Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same
HUP0000720A3 (en) Imidazo [1,2-a] pyridine derivatives, process for their preparation, pharmaceutical formulation containing them and their use
HUP0002480A3 (en) Pyrrolo[2,1-c][1,4]benzodiazepine derivatives, their use, process for their preparation and pharmaceutical compositions containing them
HUP0003826A3 (en) Novel triazolo [4,5-b] pyrimidine derivatives, process for their preparation and pharmaceutical compositions thereof
HUP0105132A3 (en) Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions
HUP0202624A3 (en) Pyrazolo[4,3-d]pyrimidine-derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0104164A3 (en) Imidazo[4,5-c]-pyridine-4-one derivatives with factor xa inhibiting effect, pharmaceutical compositions containing the same and process for their preparation